Literature DB >> 16598378

Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model.

Katrien Venken1, Karel De Gendt, Steven Boonen, Jill Ophoff, Roger Bouillon, Johannes V Swinnen, Guido Verhoeven, Dirk Vanderschueren.   

Abstract

UNLABELLED: The relative importance of AR and ER activation has been studied in pubertal male AR knockout and WT mice after orchidectomy and androgen replacement therapy, either with or without an aromatase inhibitor. AR activation dominates normal trabecular bone development and cortical bone modeling in male mice. Moreover, optimal periosteal bone expansion is only observed in the presence of both AR and ER activation.
INTRODUCTION: Androgen receptor (AR)-mediated androgen action has traditionally been considered a key determinant of male skeletal growth. Increasing evidence, however, suggests that estrogens are also essential for normal male bone growth. Therefore, the relative importance of AR-mediated and estrogen receptor (ER)-mediated androgen action after aromatization remains to be clarified.
MATERIALS AND METHODS: Trabecular and cortical bone was studied in intact or orchidectomized pubertal AR knockout (ARKO) and male wildtype (WT) mice, with or without replacement therapy (3-8 weeks of age). Nonaromatizable (dihydrotestosterone [DHT]) and aromatizable (testosterone [T]) androgens and T plus an aromatase inhibitor (anastrazole) were administered to orchidectomized ARKO and WT mice. Trabecular and cortical bone modeling were evaluated by static and dynamic histomorphometry, respectively.
RESULTS: AR inactivation or orchidectomy induced a similar degree of trabecular bone loss (-68% and -71%, respectively). Both DHT and T prevented orchidectomy-induced bone loss in WT mice but not in ARKO mice. Administration of an aromatase inhibitor did not affect T action on trabecular bone. AR inactivation and orchidectomy had similar negative effects on cortical thickness (-13% and -8%, respectively) and periosteal bone formation (-50% and -26%, respectively). In orchidectomized WT mice, both DHT and T were found to stimulate periosteal bone formation and, as a result, to increase cortical thickness. In contrast, the periosteum of ARKO mice remained unresponsive to either DHT or T. Interestingly, administration of an aromatase inhibitor partly reduced T action on periosteal bone formation in orchidectomized WT mice (-34% versus orchidectomized WT mice on T), but not in ARKO mice. This effect was associated with a significant decrease in serum IGF-I (-21% versus orchidectomized WT mice on T).
CONCLUSIONS: These findings suggest a major role for AR activation in normal development of trabecular bone and periosteal bone growth in male mice. Moreover, optimal stimulation of periosteal growth is only obtained in the presence of both AR and ER activation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16598378     DOI: 10.1359/jbmr.060103

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  51 in total

Review 1.  Building strong bones: molecular regulation of the osteoblast lineage.

Authors:  Fanxin Long
Journal:  Nat Rev Mol Cell Biol       Date:  2011-12-22       Impact factor: 94.444

2.  Metastasin S100A4 is a mediator of sex hormone-dependent formation of the cortical bone.

Authors:  Malin C Erlandsson; Li Bian; Ing-Marie Jonsson; Karin M Andersson; Maria I Bokarewa
Journal:  Mol Endocrinol       Date:  2013-06-24

3.  Battle of the sex steroids in the male skeleton: and the winner is....

Authors:  Thomas J Weber
Journal:  J Clin Invest       Date:  2016-02-22       Impact factor: 14.808

4.  Sex steroids during bone growth: a comparative study between mouse models for hypogonadal and senile osteoporosis.

Authors:  J Ophoff; K Venken; F Callewaert; S Boonen; R Bouillon; D Vanderschueren
Journal:  Osteoporos Int       Date:  2009-02-24       Impact factor: 4.507

Review 5.  [Pharmaceutical therapy of bone metabolism disorders in chronic kidney disease mineral bone disorder (CKD-MBD) with special respect to antiresorptive substances].

Authors:  G Lehmann; G Wolf
Journal:  Z Rheumatol       Date:  2014-05       Impact factor: 1.372

6.  Sex-Dependent, Osteoblast Stage-Specific Effects of Progesterone Receptor on Bone Acquisition.

Authors:  Zhendong A Zhong; Alexander Kot; Yu-An E Lay; Hongliang Zhang; Junjing Jia; Nancy E Lane; Wei Yao
Journal:  J Bone Miner Res       Date:  2017-07-13       Impact factor: 6.741

Review 7.  The role of estrogen and androgen receptors in bone health and disease.

Authors:  Stavros C Manolagas; Charles A O'Brien; Maria Almeida
Journal:  Nat Rev Endocrinol       Date:  2013-09-17       Impact factor: 43.330

8.  The role of activation functions 1 and 2 of estrogen receptor-α for the effects of estradiol and selective estrogen receptor modulators in male mice.

Authors:  Anna E Börjesson; Helen H Farman; Cecilia Engdahl; Antti Koskela; Klara Sjögren; Jenny M Kindblom; Alexandra Stubelius; Ulrika Islander; Hans Carlsten; Maria Cristina Antal; Andrée Krust; Pierre Chambon; Juha Tuukkanen; Marie K Lagerquist; Sara H Windahl; Claes Ohlsson
Journal:  J Bone Miner Res       Date:  2013-05       Impact factor: 6.741

9.  Prepubertal OVX increases IGF-I expression and bone accretion in C57BL/6J mice.

Authors:  Kristen E Govoni; Jon E Wergedal; Robert B Chadwick; Apurva K Srivastava; Subburaman Mohan
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-09-23       Impact factor: 4.310

Review 10.  Recent experimental and clinical findings in the skeleton associated with loss of estrogen hormone or estrogen receptor activity.

Authors:  Eric P Smith; Bonny Specker; Kenneth S Korach
Journal:  J Steroid Biochem Mol Biol       Date:  2009-11-10       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.